Zanzalintinib

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameZanzalintinib
Drug Alias NameXL-092
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsVascular endothelial growth factor receptor antagonistsVascular endothelial growth factor receptor 2 antagonists +[5] 
TargetsVascular endothelial growth factor receptorHepatocyte growth factor receptorVascular endothelial growth factor receptor 2 +[5] 
Therapy Area/IndicationsBone metastasesPancreatic neuroendocrine tumors (pNET)Poorly Differentiated Thyroid Gland Carcinoma +[37] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[39] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesExelixis Inc
China Registration ClassN/A

Develop Information

Active CompaniesUtah State UniversityWashington University School Of MedicineThe University Of Chicago +[8] 
Inactive CompaniesN/A
Active IndicationsBone metastasesPancreatic neuroendocrine tumors (pNET)Poorly Differentiated Thyroid Gland Carcinoma +[36] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG